Eli Lilly Stock Strengthens as Bernstein Reaffirms Outperform Rating on Expanding GLP-1 Pipeline and Long-Term Growth Strategy
Eli Lilly, one of the most valuable pharmaceutical companies globally, continues to attract Wall Street’s attention. Bernstein SocGen Group reaffirmed its Outperform rating with a price target of $1,300 per share. This endorsement highlights Lilly’s strong presence in the growing GLP-1 drug market, its ongoing pipeline expansion, and its leadership in therapies for obesity and…
